Scarica l'app Stockscreener
82.93
1.18%
-0.99
Dopo l'orario di chiusura:
82.93
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
Mirum Pharmaceuticals Is Maintained at Outperform by Baird - Moomoo
EBITDA of Mirum Pharmaceuticals, Inc. – HAN:08D - TradingView
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV - Zacks Investment Research
Is Mirum Pharmaceuticals (MIRM) Undervalued On New Brelo Vitug Trial Data? - Yahoo Finance
Mirum's liver infection drug lowers virus levels in late-stage study - reuters.com
Citizens raises Mirum Pharmaceuticals stock price target on HDV data By Investing.com - Investing.com Canada
Mirum Pharmaceuticals, Meta, Boeing - TradingView
HC Wainwright & Co. maintains Buy rating on Mirum Pharmaceuticals, $195 price target - TradingView
Stifel reiterates Mirum Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Canada
Mirum Pharmaceuticals Announces FDA Approval of Atebrioz and Positive Phase 3 Data for Hepatitis Delta - Kalkine Media
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis DeltaSlideshow (NASDAQ:MIRM) 2026-09-28 - Seeking Alpha
FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease - biospace.com
Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment - Benzinga
What Does Mirum Pharmaceuticals's (NASDAQ:MIRM) Latest Move Mean for Healthcare Stocks Investors? - Kalkine Media
Mirum Pharmaceuticals, Inc. Meets Primary Endpoint In Phase 3 AZURE-1 Study Of Brelovitug In Chronic Hepatitis Delta Virus - marketscreener.com
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 - Business Wire
Mirum Pharma wins FDA nod for Atebrioz - thepharmaletter.com
Mirum and Incyte gain approval of zilurgisertib for rare bone disorder - Seeking Alpha
MIRM5806400 Bond Profile: Coupon and Redemption - TradingView
Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP patients 12 and older - Mugglehead Investment Magazine
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva - Business Wire
Mirum Pharmaceuticals wins Bay Area's 14th drug approval this year - The Business Journals
Why is Mirum Pharmaceuticals stock gaining today? By Investing.com - Investing.com Canada
US FDA approves Mirum's drug for rare bone disorder - reuters.com
Bay Area company readies for decision on drug to treat alarming 'stone man' syndrome - The Business Journals
Mirum Pharmaceuticals (MIRM) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Mirum Pharmaceuticals stock trades at USD 98.22 as targets reach USD 137.31 - AD HOC NEWS
(MIRM) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Mirum Pharmaceuticals Names Rob Myers Chief Medical Officer - Contract Pharma
Mirum Pharmaceuticals stock pulls back as Bank of America reveals new stake and valuation stays belo - AD HOC NEWS
Mirum Pharmaceuticals Falls 7.1% as Investors Appear to Reassess Near-Term Biotech Catalysts - moomoo.com
Mirum Pharmaceuticals: Oversold And Set To Rally On Critical Pipeline-Related Events - Seeking Alpha
Mirum Pharmaceuticals at Morgan Stanley conference: growth meets key catalysts - Investing.com Canada
Mirum Pharmaceuticals Chief Financial Officer Sold Shares Worth Over $978K - TradingView
Mirum Pharma (MIRM) officer to sell shares to cover equity taxes - Stock Titan
Mirum Pharmaceuticals (MIRM) CFO offloads shares after RSUs vest - Stock Titan
Mirum Pharmaceuticals at H.C. Wainwright conference: growth, catalysts By Investing.com - Investing.com UK
Mirum Pharmaceuticals: The September PDUFA Is The Smallest Catalyst - Seeking Alpha
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Citizens reiterates Mirum Pharmaceuticals stock rating at outperform By Investing.com - Investing.com Canada
Precision Trading with Mirum Pharmaceuticals Inc. (MIRM) Risk Zones - Stock Traders Daily
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead - Investing.com India
Mirum Pharmaceuticals at Cantor healthcare conference: rare-disease push By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals Hires LMH Strategic Solutions - Legis1
Mirum Pharmaceuticals, Inc. Announces Management Changes - marketscreener.com
Chief medical shake-up at Mirum Pharmaceuticals (NASDAQ: MIRM) includes new leader and exit deal - Stock Titan
Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer - Yahoo Finance
MIRM stock gains on strong Q2 2026 revenue growth - ad-hoc-news.de
Mirum Pharmaceuticals SVP Howe Jolanda Disposes of 658 Shares at $100 Each (NASDAQ: MIRM) - Kalkine Media
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report? - Yahoo Finance
Mirum Pharmaceuticals global controller sells $65,800 in stock By Investing.com - Investing.com Australia
Mirum Pharmaceuticals global controller sells $65,800 in stock - investing.com
Mirum Pharmaceuticals SVP Jolanda Howe Sells 658 Shares via 10b5-1 Trading Plan - Kalkine Media
Mirum Pharmaceuticals CEO Christopher Peetz Executes Stock Option and Sells Shares Under 10b5-1 Plan - Kalkine Media
Mirum Pharma (NASDAQ: MIRM) exec sells 658 shares under preset plan - Stock Titan
Mirum Pharmaceuticals (MIRM) CEO trades 30,000 shares under preset plan - Stock Titan
Officer who sold $4M of Mirum (NASDAQ: MIRM) stock plans another sale - Stock Titan
Five investor conferences are on Mirum’s September schedule - Stock Titan
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):